IL2 and melanoma: Moreover, in a human melanoma xenograft model, we observed that the anti-syndecan-1 antibody OC-46F2, administered either as monotherapy or in combination with the immunocytokine L19-IL2, inhibited tumor growth, inducing a dramatic decrease of vascular density and loss of VM structures [25].